Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study of Safety and Efficacy Of Alpharadin With Docetaxel In Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Next Previous
Search
Trial Profile

A Phase I/IIa Study of Safety and Efficacy Of Alpharadin With Docetaxel In Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radium 223 chloride (Primary) ; Dexamethasone; Docetaxel; Prednisone
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Bayer

    • Most Recent Events

    • 10 May 2019 Results assessing safety and effectiveness of radium-223 in combination with docetaxel published in the European Journal of Cancer.
    • 18 Feb 2017 Results analysing effects of radium-223 with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer, presented at the 2017 Genitourinary Cancers Symposium.
    • 07 Jun 2016 Results (n=53) analyzing safety presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top